organization · Reporting owner
PureTech LYT, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Seaport Therapeutics, Inc.
Report date May 04, 2026 · Filed May 06, 2026
Jointly reported with PureTech Health plc
Section 16 reporting ended · disclosed 2026-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,685,013 |
Last balance in matching sequence
After 2026-05-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-05-04 · Conversion · Acquired 12,736,014 · Balance 13,038,493 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Row 2 · 2026-05-04 · Conversion · Acquired 2,681,265 · Balance 15,719,758 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Row 3 · 2026-05-04 · Conversion · Acquired 965,255 · Balance 16,685,013 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 40,000,000 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 8,421,052 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-04 · Conversion · Disposed 3,031,578 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries B Preferred Stock · Derivative | 3,031,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 6 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 965,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries A-2 Preferred Stock · Derivative | 8,421,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 5 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,681,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries A-1 Preferred Stock · Derivative | 40,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 4 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 12,736,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 965,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 3 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,685,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 2,681,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 2 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,719,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 12,736,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,038,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.